目的 探索心脉通胶囊联合维拉帕米治疗高血压的临床效果。方法 选取了2017年9月—2020年9月平顶山市第二人民医院收治的128例高血压患者为研究对象，按照随机数字表法分为对照组和治疗组，每组各64例。对照组口服盐酸维拉帕米缓释片，1片/次，2次/d；治疗组在对照组基础上口服心脉通胶囊，3粒/次，3次/d。两组均连续服用4周。观察两组的临床疗效，比较两组治疗前后血压和血清细胞因子的变化情况及不良反应发生情况。结果 治疗后，治疗组总有效率89.06%，显著高于对照组76.66%（P<0.05）。治疗后，两组舒张压、收缩压均较治疗前显著降低（P<0.05）；且治疗后治疗组舒张压、收缩压显著低于对照组（P<0.05）。治疗后，治疗组血清C反应蛋白（CRP）、基质金属蛋白酶9（MMP-9）、转化生长因子β1（TGF-β1）、单核细胞趋化因子（MCP）水平均显著降低（P<0.05）；且治疗后，治疗组血清细胞因子水平显著低于对照组（P<0.05）。治疗过程中，治疗组患者不良反应发生率是3.13%，显著低于对照组的18.75%（P<0.05）。结论 心脉通胶囊联合维拉帕米治疗高血压患者具有较好的临床疗效，可降低血压指标和炎性因子水平，适合临床推广应用。

Objective To explore the clinical effect of Xinmaitong Capsules combined with verapamil in treatment of hypertension. Methods A total of 128 patients with hypertension admitted to the Second People's Hospital of Pingdingshan from September 2017 to September 2020 were selected as the research objects, and they were divided into control and treatment group according to the random number table method, with 64 cases in each group. Patients in the control group were po administered with Verapamil Hydrochloride SR Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Xinmaitong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of blood pressure and serum cytokines were compared between the two groups before and after treatment. The incidence of adverse reactions in the two groups was observed. Results After treatment, the total effective rate in treatment group was 89.06%, which was significantly higher than 76.66% in control group (P < 0.05). After treatment, diastolic blood pressure and systolic blood pressure in both groups were significantly decreased compared with before treatment (P < 0.05). After treatment, diastolic blood pressure and systolic blood pressure in treatment group were significantly lower than those in control group (P < 0.05). After treatment, the levels of serum C-reactive protein (CRP), matrix metalloproteinase 9 (MMP-9), transforming growth factor β1 (TGF-β1) and monocyte chemokine (MCP) in treatment group were significantly decreased (P < 0.05). After treatment, serum cytokine level in treatment group was significantly lower than that in control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 3.13%, significantly lower than 18.75% in the control group (P < 0.05). Conclusions Xinmaitong Capsules combined with verapamil has good clinical effect in treatment of hypertension, and can reduce the level of blood pressure index and inflammatory factors, which is suitable for clinical application.

R972

河南省平顶山市科技计划项目（2018-79）